Abstract 1858P
Background
Identifying the patient's discomfort and unmet needs is crucial for providing effective care. However, accurately understanding the patient's discomfort can be challenging due to various limitations in the medical field, and in some cases, their discomfort may be underestimated. To better understand the difficulties faced by cancer patients, we implemented Social Listening to identify areas where improved treatment may be provided.
Methods
From October 1, 2021 to September 30, 2022, we gathered online data related to cancer and anti-cancer treatments. Using NetBase as our social listening platform, we filtered out irrelevant and commercial content from the collected data.
Results
A total of 169,575 social mentions related to cancer and anticancer treatment were collected. Among them, 12% (n=20,899) addressed the challenges experienced by patients following a cancer diagnosis. These challenges were further categorized based on the content of social media posts, with 52% focusing on physical difficulties, 42% on emotional challenges, and 6% on difficulties related to daily life. Emotional difficulties such as worry, denial, depression, fear, and anxiety were prevalent among cancer patients, with variations in priority depending on the time of diagnosis, treatment, and post-treatment stages. Of the 16,743 social media discussions related to cancer care, only 9% were related to managing emotional stress. A majority (84%) of discussions related to mental health management involved receiving psychiatric treatment, with the remaining 16% focusing on self-help groups, communication with others, meditation, hobbies, and religious practices.
Conclusions
Emotional burdens, along with physical difficulties, were frequently discussed on social media. However, there appeared to be a relative lack of focus on the management of emotional burdens. Considering the known association between emotional management and cancer treatment outcomes, it is imperative for physicians to prioritize their patients' emotional well-being and offer appropriate support.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Korean Society of Medical Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05